Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The pursuit of non-invasive treatment for intracranial aneurysms to PRevent aneurYSMal subarachnoid hemorrhage

Project description

Non-invasive treatments to prevent aneurysm rupture

An aneurysm forms when a weakened section of a blood vessel wall bulges outward due to pressure from blood flow. Rupture of intracranial aneurysms can cause aneurysmal subarachnoid haemorrhage and stroke. Most patients go untreated since current preventive measures are invasive and risky. There is an urgent need for safe, non-invasive therapies, but limited knowledge of the underlying disease pathways has hampered progress. The ERC-funded Treat-PRYSM project aims to repurpose existing drugs targeting vascular disease mechanisms such as endothelial-to-mesenchymal transition and TGF-β signalling. By also investigating gender-specific influences, Treat-PRYSM will open new paths for preventing aneurysm rupture through innovative drug-based strategies.

Objective

Rupture of intracranial aneurysms (IA) results in aneurysmal subarachnoid hemorrhage (aSAH), an often fatal type of stroke. Invasive IA treatment to prevent aSAH is a high-risk procedure, limiting its use and leaving most IA patients untreated. Thus, there is an urgent need for non-invasive drugs preventing aSAH, but these are lacking as our understanding of the causal disease pathways is poor. The considerable female predominance in IA and aSAH suggests the existence of sex-specific regulation of these pathways. In the ERC PRYSM StG we identified candidate drugs lisinopril, amlodipine, tamsulosin, simvastatin and metformin associated with a reduced risk of aSAH. These targets have an inhibitory effect on the Transforming Growth Factor-β (TGF-β) pathway, a potent inducer of Endothelial-to-Mesenchymal transition (EndMT), a driver of vascular disease.

The Treat-PRYSM team’s main aim is to transition the research from the ERC PRYSM StG into innovation by performing the following activities:

1) Confirm and validate our 5 candidate drugs—lisinopril, amlodipine, tamsulosin, simvastatin and metformin—as effective drugs in reducing aSAH incidence, by employing the principle of drug repurposing and triangulating evidence from epidemiological and genetic data.
2) Find genetic evidence that the EndMT and TGF-β pathways are involved in IA pathogenesis, thereby identifying these pathways as potential therapeutic targets for the candidate drugs, using a large-scale genomics approach.
3) Determine whether the mode of action of the candidate drugs and EndMT/TGF-β pathways is influenced by sex.
4) Evaluate the opportunities for a clinical trial of the most promising candidate drug to assess its ability to inhibit growth of IAs, serving as a surrogate marker for rupture.

This approach will ultimately provide a non-invasive, cost-effective drug to prevent aSAH in patients with unruptured IAs and will significantly enhance our understanding of the disease's causal pathways.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Net EU contribution
€ 70 000,00
Address
HEIDELBERGLAAN 100
3584 CX Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)